The acquisition provides WCCT Global with expanded early phase capabilities in its ophthalmology center in cornea and external disease, uveitis, vitreoretinal diseases, glaucoma, neuro-ophthlamology, oculoplastics and pediatric ophthalmic conditions such as Strabismus and Amblyopia.
Dr. Michael A. Sheety, WCCTG’s medical and surgery director of ophthalmology and aesthetics, said, “The new team brings more than 75 combined years of clinical and research experience in ophthalmology and aesthetics.”
WCCT now owns and operates five sites, including two Clinical Pharmacology Units (CPUs) with more than 180 beds. WCCT’s ophthalmic patient database has grown ten-fold with patients of varying ages and demographics. Additionally, with an ophthalmology and optometry referral network of more than 20 facilities in southern California, WCCT now has direct access to more than 40,000 ophthalmology and optometry patients. In the cosmetology and aesthetics space, WCCT’s network has grown to more than 45 physicians throughout southern California.
